Ipsen (Paris: IPN), an innovation-driven global specialty pharmaceutical group, today announced that Dysport® is now available in the United States for the treatment of cervical dystonia in adults.
Dysport® is the latest addition to the growing range of Ipsen’s drugs already available in North America, both in endocrinology with Somatuline® Depot and Increlex®, and in neurology, with Apokyn®.
Christophe Jean, Executive Vice President, Operations of the Ipsen Group said: “The launch of Dysport® in its therapeutic indication for the treatment of cervical dystonia in the United States is undoubtedly a significant milestone to strengthen Ipsen's presence in North America. We are very pleased to be able to offer physicians a new and important treatment option for their patients suffering from cervical dystonia. Dysport®, together with Somatuline® and Increlex®, becomes Ipsen’s third product to be available globally. With the achievement of this key milestone, I wish to congratulate and thank the teams that are making this launch a reality thanks to their hard work and dedication reflective of an efficient organization.”
SickKids study offers new path for pediatric rare disease clinical trials